



## Please Fax Completed Form To: 888-898-9113

Please Send a Copy of The Patient's Insurance Cards (Front & Back)

PATIENT INFORMATION (Complete or Fax Existing Chart)		PRESCRIBER INFORMATION	
Name:		Prescriber Name:	
INSURANCE INFORMATION – OR – Send a copy of the patient's prescription/insurance cards (front & back)			
Primary Insurance: Plan #: Group #: RX Card (PBM): BIN:	PCN:	Secondary Insurance (If Applicable): Plan #: Group #: RX Card (PBM): BIN: PCN: _	
CLINICAL INFORMATION			
□ L40.0 Plaque Psoriasis (Ps) □ L40.52 Psoriatic Arthritis Mutilans □ K50.90 Crohn's Disease □ Other Diagnosis/ICD-10 Code:  TB Test (Date):// Results: □ Positive □ Negative  Lab Orders: Frequency:			
SKYRIZI™ ORDERS			
Prescription type:  New start  Restart Continued therapy Total Doses Received: Date of Last Injection/Infusion:			
Medication	Dose/	'Frequency	Refills
□ Skyrizi™ (risankizumabrzaa)	□ Loading dose: 600mg/10mL vial     □ Infuse 600mg IV at weeks 0, 4 and 8     □ Other:     □ Patient does not need loading dose     □ Maintenance dose: 360mg/2.4mL prefilled cartridge with On-Body Injector (OBI)     □ Inject 360mg subcutaneously on week 12 and every 8 weeks thereafter     □ Other:		Refills:
□ Skyrizi™ (risankizumabrzaa) – Psoriasis Indicated	☐ 150 mg (via one 150 mg injection or two 75 mg injections) subcutaneously at week 0 and week 4, followed by 150 mg subcutaneously every 12 weeks ☐ Other:		Refills:
Special Instructions:			
SIGNATURE			
We hereby authorize Talis Healthcare LLC to provide all supplies and additional services (nursing/patient training) required to provide and deliver the medicine as prescribed in this referral.  X			

To ensure payment by insurance carrier, please include supporting clinical documentation for specified ICD 10 Code, demographic, and insurance information along with faxed order. Initial appointment will be verified upon insurance approval.

CONFIDENTIALITY STATEMENT: This facsimile and documents accompanying this transmission contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender at the address and telephone number set forth herein and arrange for return or destruction of the material. In no event should such material be read by anyone other than the named addressee, except by express authority of the sender to the named addressee.